BioLife Solutions Stock (NASDAQ:BLFS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$22.43

52W Range

$14.84 - $29.55

50D Avg

$24.95

200D Avg

$24.75

Market Cap

$1.06B

Avg Vol (3M)

$409.14K

Beta

1.93

Div Yield

-

BLFS Company Profile


BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

159

IPO Date

Nov 22, 1989

Website

BLFS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Service$160.00K$17.55M-
Product$76.03M$117.69M-
Rental Revenue$6.07M$8.03M$4.63M
Service Revenue--$210.00K

Fiscal year ends in Dec 24 | Currency in USD

BLFS Financial Summary


Dec 24Dec 23Dec 22
Revenue$82.25M$143.27M$161.76M
Operating Income$-11.39M$-70.83M$-39.91M
Net Income$-20.18M$-66.43M$-139.81M
EBITDA$-11.39M$-45.24M$-23.19M
Basic EPS$-0.44$-1.52$-3.29
Diluted EPS$-0.44$-1.52$-3.29

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q4 24Mar 03, 25 | 8:00 AM
Q3 24Nov 12, 24 | 4:30 PM
Q1 24May 09, 24 | 5:58 PM

Peer Comparison


TickerCompany
ATRAptarGroup, Inc.
RMDResMed Inc.
ICUIICU Medical, Inc.
KRMDKORU Medical Systems, Inc.
AKYAAkoya Biosciences, Inc.
COOThe Cooper Companies, Inc.
ATRCAtriCure, Inc.
WSTWest Pharmaceutical Services, Inc.
TFXTeleflex Incorporated
HAEHaemonetics Corporation
ANGOAngioDynamics, Inc.
ALCAlcon Inc.